Zobrazeno 1 - 10
of 21
pro vyhledávání: '"K. Lytkina"'
Publikováno v:
Annals of the Rheumatic Diseases. 81:848-849
BackgroundRetention on therapy is the most important integrative indicator of the success of the drug, reflecting both the effectiveness and tolerability and general acceptability of treatment. This indicator can be evaluated with high accuracy in ob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da1ae7b2ae0c538200c77fa1cff4aca4
https://doi.org/10.1136/annrheumdis-2022-eular.2939
https://doi.org/10.1136/annrheumdis-2022-eular.2939
Autor:
Tatiana Kruglova, Oleg Melikhov, Grigory Rodoman, Gleb Putsman, Alena Zagrebneva, Justin Stebbing, Elena A. Prokhorovich, Georgy Melkonyan, K. Lytkina, Arkady Vertkin
Publikováno v:
Annals of the Rheumatic Diseases
Janus kinase (JAK) inhibitors for the treatment of hospitalised patients with COVID-19 have been extensively studied. Initially, at the start of the pandemic outside of China, baricitinib was shown using artificial intelligence to have a potential du
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fb885959dcf387701854ccd084e1c12
http://hdl.handle.net/10044/1/89830
http://hdl.handle.net/10044/1/89830
Autor:
E. Zhilyaev, G. Lukina, E. Koltsova, D. Murtazalieva, E. Shmidt, K. Lytkina, A. Shmitko, D. Blagovidov, M. Kostinov
Publikováno v:
Annals of the Rheumatic Diseases. 81:1278.2-1279
BackgroundThe incidence of infections, mainly pneumonias, is significantly increased in patients with rheumatoid arthritis (RA). The risk increases more in persons treated with targeted anti-inflammatory drugs (tDMARDs), biological or targeted synthe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5fabec14efc45c5de868c6d3fbb25093
https://doi.org/10.1136/annrheumdis-2022-eular.3801
https://doi.org/10.1136/annrheumdis-2022-eular.3801
Publikováno v:
Annals of the Rheumatic Diseases. 81:1211.1-1211
BackgroundThe main goal of rheumatoid arthritis (RA) patients therapy is to achieve low activity or remission of the disease (T2T strategy). However, it is sometimes necessary to interrupt effective treatment due to the development of adverse events.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::570fa289fc07e5722f7d555372685c27
https://doi.org/10.1136/annrheumdis-2022-eular.1030
https://doi.org/10.1136/annrheumdis-2022-eular.1030
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Psoriatic arthritis.
Background Early started therapy of psoriatic arthritis with the goal to achieve minimal disease activity can slow the joint damage progression. Data concerning the persistence of psoriatic arthritis (PsA) patients on biologics in real clinical pract
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df50f44a9186818d9ae3b169d7df8312
https://doi.org/10.1136/annrheumdis-2019-eular.4335
https://doi.org/10.1136/annrheumdis-2019-eular.4335
Publikováno v:
Abstracts Accepted for Publication.
Background Moscow Unified Arthritis Registry (MUAR) started at 01 DEC 2012. By 01 DEC 2017, 829 RA patients were included in the register. Objectives The aim of the study was to evaluate the effectiveness and treatment survival of TOFA and identify p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8959b88583ab91c69ac724919a09aa9e
https://doi.org/10.1136/annrheumdis-2019-eular.3783
https://doi.org/10.1136/annrheumdis-2019-eular.3783
Publikováno v:
Annals of the Rheumatic Diseases. 80:1383.3-1384
Background:WHO declared the COVID-19 outbreak as a pandemic on March 12th, 2020. Assessing the risk of severe course in patients with rheumatic diseases, especially those who receive targeted immunosuppressive treatment, is an urgent problem for rheu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db5e8c7d4654b5ff31c454dce6c65700
https://doi.org/10.1136/annrheumdis-2021-eular.3867
https://doi.org/10.1136/annrheumdis-2021-eular.3867
Publikováno v:
Annals of the Rheumatic Diseases. 80:1265.1-1265
Background:This study is the first analysis of biological disease-modifying antirheumatic drugs (bDMARDs) for ankylosing spondylitis (AS) within the Moscow Unified Arthritis Register (MUAR).Objectives:to compare the effectiveness of bDMARDs in patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6216ec5aab3333991cccee6fc2d18a3
https://doi.org/10.1136/annrheumdis-2021-eular.2819
https://doi.org/10.1136/annrheumdis-2021-eular.2819
Publikováno v:
Annals of the Rheumatic Diseases. 80:731.3-732
Background:The number of new biologics in treatment of axial spondyloarthritis (axSpA) is rapidly increasing. It is important to assess timely their place in the treatment of axSpA, especially with regard to retention on therapy.Objectives:To compare
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::688b4b2304c432bc69f0d6b5bf0b41c4
https://doi.org/10.1136/annrheumdis-2021-eular.3642
https://doi.org/10.1136/annrheumdis-2021-eular.3642